BackgroundCheck.run
Search For

Paul William Hollenbach, 60Hayward, CA

Known as:
Paul W Hollenbach Paul D Hollenbach Paul W Hollendach
Related to:
Kwang Juan 70 Cathy L Hollenbach Stanley J Hollenbach 66 Nicholas Galletta 39 Justin M Hollenbach 42 Molvina L Hollenbach 62 Donna T Hollenbach 58 Catherine M Hollenbach 66 John D Hollenbach 57 Benny W Chang 64 Laura J Kellems 42 Tiffany C Chang 38 Lamching Yee Yvonne Tiffany C Chang

Paul Hollenbach Phones & Addresses

Castro Valley, CA   

2460 W Bayshore Rd #3, Palo Alto, CA 94303    415-8529759   

Raleigh, NC   

Durham, NC   

1600 E 3Rd Ave #2712, San Mateo, CA 94401    650-8529759   

South San Francisco, CA   

Get Report
Control this profile

Mentions for Paul William Hollenbach

Paul Hollenbach resumes & CV records

Resumes

Paul Hollenbach Photo 18

Paul Hollenbach

Paul Hollenbach Photo 19

Paul Hollenbach

Publications & IP owners

Us Patents

Treatment Of Melanoma

US Patent:
2010008, Apr 8, 2010
Filed:
Mar 7, 2008
Appl. No.:
12/530231
Inventors:
Carla C. Heise - Benicia CA, US
Paul Hollenbach - Castro Valley CA, US
Daniel Menezes - Emeryville CA, US
Nancy Pryer - Kensington CA, US
Katherine Rendahl - Berkeley CA, US
Marion Wiesmann - Brisbane CA, US
Assignee:
NOVARTIS AG - Basel
International Classification:
A61K 31/496
A61P 35/00
A61K 33/24
A61K 31/655
A61K 31/662
A61K 38/12
A61K 38/20
A61K 38/21
US Classification:
424 852, 51425307, 424649, 514151, 514115, 514 9, 424 854, 424 857
Abstract:
Methods of treating melanoma include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The compound, tautomer, salt of the compound, salt of the tautomer, or mixture thereof may be used to prepare medicaments for treating metastatic cancer. The variable A has the values defined herein.

Treatment Of A Hematologic Malignancy With 2-(4-Chlorophenyl)-N-((2-(2,6-Dioxopiperidin-3-Yl)-1-Oxoisoindolin-5-Yl)Methyl)-2,2-Difluoroacetamide

US Patent:
2021015, May 27, 2021
Filed:
Jul 2, 2020
Appl. No.:
16/920267
Inventors:
- Summit NJ, US
Paul Hollenbach - Castro Valley CA, US
Kyle MacBeth - San Francisco CA, US
Michael Pourdehnad - San Francisco CA, US
Irit Rappley - San Diego CA, US
Gang Lu - San Diego CA, US
International Classification:
A61K 31/454
A61K 9/00
A61K 9/19
Abstract:
Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.

Treatment Of A Hematologic Malignancy With 2-(4-Chlorophenyl)-N-((2-(2,6-Dioxopiperidin-3-Yl)-1-Oxoisoindolin-5-Yl)Methyl)-2,2-Difluoroacetamide

US Patent:
2019017, Jun 13, 2019
Filed:
Feb 13, 2019
Appl. No.:
16/275234
Inventors:
- Summit NJ, US
Paul Hollenbach - Castro Valley CA, US
Kyle MacBeth - San Francisco CA, US
Michael Pourdehnad - San Francisco CA, US
Irit Rappley - San Diego CA, US
Gang Lu - San Diego CA, US
International Classification:
A61K 31/454
A61K 9/19
A61K 9/00
Abstract:
Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.

Methods For Determining Drug Efficacy For The Treatment Of Diffuse Large B-Cell Lymphoma, Multiple Myeloma, And Myeloid Cancers

US Patent:
2019000, Jan 3, 2019
Filed:
Apr 5, 2018
Appl. No.:
15/946618
Inventors:
- Summit NJ, US
Patrick HAGNER - Sparta NJ, US
Courtney G. HAVENS - Morristown NJ, US
Rajesh CHOPRA - Summit NJ, US
Anita GANDHI - Bernardsville NJ, US
Anke KLIPPEL - Westfield NJ, US
Maria Yinglin WANG - San Diego CA, US
Mike BREIDER - Cardiff-by-the-Sea CA, US
Suzana Sturlini COUTO - La Jolla CA, US
Yan REN - San Diego CA, US
Paul HOLLENBACH - Castro Valley CA, US
Kyle MACBETH - San Francisco CA, US
International Classification:
G01N 33/50
G01N 33/68
A61K 31/454
A61K 31/517
A61K 31/5377
A61K 38/21
C12Q 1/6883
C12Q 1/6886
G01N 33/574
Abstract:
Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.

Treatment Of A Hematologic Malignancy With 2-(4-Chlorophenyl)-N-((2-(2,6-Dioxopiperidin-3-Yl)-1-Oxoisoindolin-5-Yl)Methyl)-2,2-Difluoroacetamide

US Patent:
2017034, Dec 7, 2017
Filed:
Jun 5, 2017
Appl. No.:
15/614434
Inventors:
- Summit NJ, US
Paul Hollenbach - Castro Valley CA, US
Kyle MacBeth - San Francisco CA, US
Michael Pourdehnad - San Francisco CA, US
Irit Rappley - San Diego CA, US
International Classification:
A61K 31/454
A61K 9/19
Abstract:
Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)--oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.

Methods For Determining Drug Efficacy For The Treatment Of Diffuse Large B-Cell Lymphoma, Multiple Myeloma, And Myeloid Cancers

US Patent:
2016031, Oct 27, 2016
Filed:
Dec 5, 2014
Appl. No.:
15/101869
Inventors:
- Summit NJ, US
Patrick Hagner - Sparta NJ, US
Courtney G. Havens - Morristown NJ, US
Rajesh Chopra - Summit NJ, US
Anita Gandhi - Bernardsville NJ, US
Anke Klippel - Westfield NJ, US
Maria Yinglin Wang - San Diego CA, US
Mike Breider - Cardiff-by-the-Sea CA, US
Suzana Sturlini Couto - La Jolla CA, US
Yan Ren - San Diego CA, US
Paul Hollenbach - Castro Valley CA, US
Kyle MacBeth - San Francisco CA, US
International Classification:
G01N 33/50
C12Q 1/68
A61K 31/5377
G01N 33/68
A61K 31/454
A61K 31/517
G01N 33/574
A61K 38/21
Abstract:
Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.

Possible Relatives

Elaine R Hollenbach  Harry C Hollenbach  Jayme A Hollenbach  Jeffrey A Hollenbach  Jessica R Hollenbach  Jil A Hollenbach  Margaret Hollenbach  Paul M Johnson  Paul Stamps  Paul B Stanaway 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.